Analyst Price Targets — XENE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 10, 2026 10:41 am | Douglas Tsao | H.C. Wainwright | $74.00 | $63.36 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Xenon Pharmaceuticals (XENE) |
| August 7, 2026 12:30 pm | Brian Abrahams | RBC Capital | $81.00 | $63.55 | TheFly | Xenon Pharmaceuticals price target lowered to $81 from $82 at RBC Capital |
| May 10, 2026 2:17 pm | Benjamin Burnett | Wells Fargo | $69.00 | $56.44 | TheFly | Xenon Pharmaceuticals price target raised to $69 from $68 at Wells Fargo |
| May 8, 2026 1:46 pm | Serge Belanger | Needham | $78.00 | $56.55 | TheFly | Xenon Pharmaceuticals price target lowered to $78 from $80 at Needham |
| March 10, 2026 8:35 am | — | Deutsche Bank | $90.00 | $60.61 | TheFly | Xenon Pharmaceuticals price target raised to $90 from $56 at Deutsche Bank |
| March 9, 2026 7:53 pm | — | RBC Capital | $80.00 | $62.76 | TheFly | Xenon Pharmaceuticals price target raised to $80 from $59 at RBC Capital |
| March 9, 2026 7:52 pm | Andrew Tsai | Jefferies | $100.00 | $62.76 | StreetInsider | Xenon Pharmaceuticals (XENE) PT Raised to $100 at Jefferies |
| March 9, 2026 6:47 pm | Yatin Suneja | Guggenheim | $90.00 | $62.76 | StreetInsider | Xenon Pharmaceuticals (XENE) PT Raised to $90 at Guggenheim |
| March 9, 2026 4:20 pm | — | Robert W. Baird | $97.00 | $62.76 | StreetInsider | Xenon Pharmaceuticals (XENE) PT Raised to $97 at Baird |
| March 9, 2026 4:20 pm | — | Morgan Stanley | $97.00 | $62.76 | StreetInsider | Xenon Pharmaceuticals (XENE) PT Raised to $97 at Baird |
Latest News for XENE
VANCOUVER, BC and BOSTON, MA, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to five new non-officer employees consisting of an aggregate of 13,450 share options and 7,850…
VANCOUVER, BC and BOSTON, MA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced multiple data presentations at the upcoming 16th European Epilepsy Congress (EEC), taking place September 5-9, 2026, in…
BlackRock Inc. bought a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ: XENE) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 7,522,482 shares of the biopharmaceutical company's stock, valued at approximately $454,057,000. BlackRock Inc. owned about 7.78% of Xenon Pharmaceuticals
Xenon Pharmaceuticals (XENE) is upgraded to "Strong Buy" following positive phase 3 X-TOLE2 results for azetukalner in focal onset seizures [FOS]. Company plans NDA filing for azetukalner in FOS in Q3 2026, with X-TOLE3 supporting potential ex-US expansion. Major depressive disorder [MDD] is a key pipeline focus, with phase 3 X-NOVA2 topline data expected in 1H 2027.
10x Genomics reported second-quarter revenue of $151 million, including $1.6 million in license and royalty revenue tied to its settlement with Takara Bio. Excluding non-recurring settlement revenue in both periods, revenue was $149.4 million, up 3% from the prior-year quarter.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for XENE.
U.S. House Trading
No House trades found for XENE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.